Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
36,274,940
-
Share change
-
-431,542
-
Total reported value
-
$386,279,169
-
Put/Call ratio
-
17%
-
Price per share
-
$10.65
-
Number of holders
-
138
-
Value change
-
-$9,614,096
-
Number of buys
-
65
-
Number of sells
-
58
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2024
As of 31 Dec 2024,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,274,940 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock, Inc., MENORA MIVTACHIM HOLDINGS LTD., TORONTO DOMINION BANK, Vestal Point Capital, LP, ACORN CAPITAL ADVISORS, LLC, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, Nantahala Capital Management, LLC, and SILVERARC CAPITAL MANAGEMENT, LLC.
This page lists
139
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.